← Eichor
Study identifier: NCT07054099 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Condition: Varicella (Chickenpox) · Chickenpox Vaccine  ·  Sponsor: GC Biopharma Corp

PhasePhase 3
Planned participants474
Who can joinAll sexes, 12 Months to 12 Years
Healthy volunteersYes

About this study

This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.

This description comes directly from the study's public registry record.

Talk to the study team

Minji Ko  ·  +82-31-260-9143  ·  mg1111d@gccorp.com

Sujin Lee  ·  mg1111d@gccorp.com

Always discuss trial participation with your own doctor first.

Locations (1)

Srinagarind HospitalKhon Kaen, Changwat Khon Kaen, ThailandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07054099